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ntracoronary Glycoprotein
Ib/IIIa Inhibitors
rom Questioning the Logic to Weighing the Data*
eter B. Berger, MD,† Patricia J. M. Best, MD‡
anville, Pennsylvania; and Rochester, Minnesota
nitially, the administration of intracoronary (IC) rather than
ntravenous (IV) glycoprotein IIb/IIIa inhibitors was met with
kepticism. It had been widely believed that the entire pool of
irculating platelets had to be inhibited, and at least 80% to
0% of platelet glycoprotein IIb/IIIa receptors bound by drugs
1). Drug doses resulting in 90% receptor binding did not
mprove clinical benefit; doses with 80% binding were
hought to paradoxically increase thrombotic events (2).
See page 928
In 1999, 6 years after the approval of abciximab, the earliest
ase reports of its IC administration described the dissolution
f intracoronary thrombus (3,4). (It is important to remember
hat studies of IC glycoprotein IIb/IIIa inhibitors have in-
olved the IC administration of only the bolus dose(s); the
tandard dose and duration of infusion has generally still been
iven IV.) The safety of this approach was suggested by a study
f 611 patients who received IC abciximab, with only 1 adverse
eaction, an allergic reaction manifested by hypotension, bron-
hospasm, and tachycardia (5). The possible superiority of IC
lycoprotein IIb/IIIa inhibitors was later suggested in a study
f 403 acute coronary syndrome patients; those receiving IC
bciximab had a statistically significant, 50% reduction in
ajor adverse cardiovascular events (MACE) compared with
hose receiving it IV (6). In another nonrandomized study of
73 percutaneous coronary intervention patients, death or
yocardial infarction (MI) was lower with IC abciximab when
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
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he Medicines Company, Corgenix/Aspirinworks, and Eli Lilly/Daiichi-Sankyo (all
or more than $10,000). Dr. Berger does not think it is relevant to this manuscript but
n case you do, Dr. Berger owns equity in Lumen, Inc. (a company that makes ana
mbolic protection device and aspiration thrombectomy catheter [greater than
10,000]). Dr. Best reports that she has no relationships to disclose.ompared with IV (5.9% vs. 13.9%, p  0.04) (7). Further
vidence in support of IC abciximab came from a randomized
rial of 154 ST-segment elevation MI patients; myocardial
erfusion was improved and infarct size was reduced with IC
ather than IV abciximab (8). In 137 patients randomized to
V versus IC abciximab, there was no difference in final TIMI
Thrombolysis In Myocardial Infarction) flow grade, but there
as a smaller troponin rise in the IC group (9). One-year
ACE was not different between the groups.
All the available glycoprotein IIb/IIIa inhibitors have
een studied using IC administration. With eptifibatide,
here were initial safety concerns because of its low pH (5.35
s. 7.2 with abciximab). However, in a study of MI patients
10,11), IC eptifibatide appeared to be safe, and over
ne-half the patients had normal myocardial perfusion at
he end of the procedure. A later study (12) of 376
ercutaneous coronary intervention patients who received a
olus of IC eptifibatide without an infusion raised the
ossibility that an IC bolus alone might decrease bleeding
omplications while still reducing MACE.
Intracoronary tirofiban has also been studied. An open-
abel, randomized study (13) of 118 acute coronary syndrome
atients demonstrated that tirofiban administered IC rather
han IV was associated with lower MACE at 14 days, although
he benefit was not sustained at 30 days. In another study (14),
4 ST-segment elevation MI patients were randomized to IV
r IC tirofiban; patients receiving IC tirofiban had better
IMI flow grades and greater ST-segment resolution.
The specific mechanisms by which IC glycoprotein IIb/IIIa
nhibitors may confer greater benefit are now being explored. A
igher local concentration might disrupt platelet cross-linking
o a greater extent, augmenting thrombus disaggregation
15,16). Intracoronary eptifibatide achieved greater glyco-
rotein IIb/IIIa receptor occupancy on platelets sampled from
he coronary sinus in MI patients than did IV administration
17). Microvascular function was also improved. It is easiest to
onceive of why IC glycoprotein IIb/IIIa inhibitors might be
uperior when there is reduced coronary artery blood flow in
hich platelet-rich thrombi are present.
If one accepts the potential superiority of IC glycoprotein
Ib/IIIa inhibitors, it is not surprising that their administration
ia a catheter within the coronary artery might be associated
ith even greater benefit. When giving a medication through
guiding catheter, it often refluxes into the aorta or, with
uiding catheters situated in the left main coronary artery,
referentially flows to the vascular bed with greater flow rather
han the vascular bed of interest. Slow flow or no-reflow
urther reduces drug delivery to the site of interest when given
hrough the guiding catheter. Thus, infusion through the
umen of an over-the-wire balloon, an aspiration catheter, or a
pecialized catheter for local drug delivery may be preferred
18). In a study comparing IC adenosine administered through
microcatheter with IV administration, IC administration had
greater effect on fractional flow reserve (19). Local drug
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936elivery may lead to a several-fold increased concentration of
he medication and, therefore, might increase its efficacy (20).
n 45 acute MI patients with TIMI flow grades 0 to 1, IC
bciximab, when compared with IV abciximab, given via a dual
umen catheter distal to the occlusion was associated with
mproved myocardial blush grade, ST-segment resolution, and
maller infarct size on scintigraphy (21). The study by Prati et
l. (22) lends additional support to the potential superiority of
dministration of abciximab well into the coronary artery,
sing optical coherence tomography to document a greater
eduction in intracoronary thrombus when abciximab was
dministered IC via the ClearwayRX Therapeutic Perfusion
atheter (Atrium Medical Corp., Hudson, New Hampshire)
ather than via the guiding catheter. To deliver the drug, the
orous balloon on the catheter is inflated to 2 to 4 atm.
nflation to “low pressures” is believed to allow drug adminis-
ration not only into the coronary lumen but also along and
erhaps into the wall of the coronary artery, with a lesser
otential for vessel wall injury.
The study had important limitations. It is small and had a
urrogate primary end point. Many patients were randomized
ut not included in the final analysis. How this porous drug
elivery balloon compares with other simpler, better studied
nd less expensive IC drug delivery methods is unknown.
Many important questions remain about the IC admin-
stration of glycoprotein IIb/IIIa inhibitors. Nonetheless,
his and other recent studies are reshaping our understand-
ng of glycoprotein IIb/IIIa inhibitors and support the role of
ocal administration. Large randomized trials supporting the
outine administration of IC glycoprotein IIb/IIIa inhibitors
re needed; several such studies are underway. Until all these
tudies are completed, the best route for glycoprotein IIb/IIIa
nhibitor administration remains unknown.
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